Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD

OBJECTIVE: During PREVENT (NCT01892345), eculizumab significantly reduced relapse risk versus placebo in patients with aquaporin‐4 immunoglobulin G‐positive neuromyelitis optica spectrum disorder (AQP4‐IgG+ NMOSD). We report an interim analysis of PREVENT's ongoing open‐label extension (OLE; NC...

Descripción completa

Detalles Bibliográficos
Autores principales: Wingerchuk, Dean M., Fujihara, Kazuo, Palace, Jacqueline, Berthele, Achim, Levy, Michael, Kim, Ho Jin, Nakashima, Ichiro, Oreja‐Guevara, Celia, Wang, Kai‐Chen, Miller, Larisa, Shang, Shulian, Sabatella, Guido, Yountz, Marcus, Pittock, Sean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248139/
https://www.ncbi.nlm.nih.gov/pubmed/33586143
http://dx.doi.org/10.1002/ana.26049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248139/
https://www.ncbi.nlm.nih.gov/pubmed/33586143
http://dx.doi.org/10.1002/ana.26049

Ejemplares similares